About darbepoetin alfa
Erythropoiesis-stimulating agent
Used for
- Treats anemia caused by chronic kidney disease.
- Treats anemia caused by chemotherapy in certain cancers.
Usual adult dose
Chronic kidney disease: usually 0.45 micrograms/kg every four weeks intravenously or under the skin. Chemotherapy: usually 2.25 micrograms/kg weekly or 500 micrograms every three weeks under the skin.
Usual dose in children
Chronic kidney disease: usually 0.45 micrograms/kg weekly, intravenously or under the skin; schedules may vary.
Common side effects
- High blood pressure
- Blood clots, including stroke or heart attack
- Injection-site pain
- Shortness of breath
Important warnings
- Use the lowest dose needed to reduce transfusions; excessive hemoglobin increases serious risks.
- Blood pressure and blood counts require monitoring.
- Rarely, pure red cell aplasia can occur; stop treatment if suspected.
- Not for anemia needing immediate correction or as a substitute for transfusion.
Pregnancy
Human pregnancy data are limited; use only when clearly needed after weighing potential risks and benefits.
Breastfeeding
It is unknown whether darbepoetin passes into breast milk; consider treatment needs and potential infant risks.
Interactions
- No major specific drug interactions are established; medicines affecting blood pressure may need review.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.